RxDoctor Payments Data

John Stahlman, NP

Psychiatric/Mental Health · Asheville, NCNPI 1811006273

Payments from drug & device makers

$5,328in general payments, 2019–2025

Across 278 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$737
  • Otsuka America Pharmaceutical, Inc.$526
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$508
  • Neurocrine Biosciences, Inc.$456
  • Alkermes, Inc.$308
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$5,07395%
  • Education$2555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,328 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,537
Medicare patients
34
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine34$374,124
Austedo XrDeutetrabenazine24$287,237
Abilify AsimtufiiAripiprazole13$77,815
Invega SustennaPaliperidone Palmitate20$74,693
VraylarCariprazine Hcl33$48,505
Abilify MaintenaAripiprazole13$37,990
RexultiBrexpiprazole17$26,988
TrintellixVortioxetine Hydrobromide45$21,984
Aripiprazole132$16,585
Clozapine138$15,924
Gabapentin204$3,401
Quetiapine Fumarate237$3,388
Olanzapine171$2,306
Divalproex Sodium ErDivalproex Sodium77$2,301
Bupropion XlBupropion Hcl179$2,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,679$661,36158 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti$526$142,79443 claims
Johnson & JohnsonInvega Sustenna$269$74,69320 claims
AbbVieVraylar$737$48,50533 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31$21,98445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →